INM

InMed Pharmaceuticals Inc. (INM) ESG Analysis Analysis (2026)

Invetso Score: 6.2/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 6.2 (Moderate)

INM's very high R&D intensity versus revenue suggests a comparatively stronger innovation-led environmental profile than peers with heavier asset footprints, though disclosure remains limited.

Low leverage and modest net debt reduce balance-sheet pressure that can constrain multi-year environmental investment, relative to more indebted peers.

The available metrics do not show direct emissions, energy, or waste data, leaving environmental performance harder to verify than for peers with fuller sustainability reporting.

A mid-range gross margin does not itself indicate environmental strength, but it implies less operational slack than peers with structurally cleaner, lower-impact processes.

Social

Score:

High R&D spending relative to revenue can support product safety, service quality, and human-capital development, giving INM a better social profile than peers with lower innovation investment.

Stock-based compensation above revenue is elevated versus typical peers, which can align employees with long-term outcomes but also raises dilution and retention scrutiny.

The provided data do not include workforce, safety, turnover, or customer-impact metrics, so social positioning remains only partially observable versus peers.

Modest leverage may support continuity of employment and stakeholder stability, but the absence of direct labor disclosures limits confidence in a stronger peer ranking.

Governance

Score:

Low debt-to-equity and net debt-to-EBITDA indicate conservative capital structure versus leveraged peers, reducing governance risk from financial distress.

Stock-based compensation at 11.3% of revenue is high relative to many peers, which can signal incentive alignment but also weaker capital discipline.

The lack of disclosed board, audit, ownership, and controversy data prevents a stronger governance assessment relative to peers with more transparent filings.

Heavy R&D investment can reflect disciplined long-term governance, yet without clearer disclosure it is difficult to distinguish strategy quality from execution risk.

Overall Score

Score:

INM screens as a mid-tier ESG name versus peers because innovation intensity and conservative leverage are positives, but limited disclosure prevents a stronger relative assessment.

Score Driver: High R&D Intensity Relative To Revenue

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on InMed Pharmaceuticals Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →